Joinhealth Snares ￥10M in Series A2 Funding Round

According to VCBeat, In June 2020, Hangzhou Joinhealth Technology Co., Ltd. ("Joinhealth") closed ￥10M Series A2 round of financing, with participation from Silicon Valley Bank, and the existing investor Sherpa Venture Capital. Robe Capital acted as the exclusive financial adviser. Proceeds from the latest round will be used to expand business in specialized disease management.

Founded in 2015, Joinhealth is an artificial intelligence (AI) company focused on health information management and healthcare services for patients. Combining with the mainstream Internet and IoT technologies, and a massive database, Joinhealth is committed to transforming disease treatment to disease management, to provide the closed-loop intelligent management of patients from discharge to readmission.

Exploring in the field of post-hospital patient management based on AI, Joinhealth provides services such as postoperative course management, specialized disease follow-up service, health education, chronic disease management, doctor-patient communication, health monitoring and other consistent post-hospital services for different users, such as the health service board of health, hospital, medical staff, and patient.

"Jishi Danao", the core product of Joinhealth, uses the intelligence-assisted technology for interaction judgment and processing, deep learning, big data processing, speech synthesis, identification, and analysis, through telephone, WeChat and other tools to help medical staffs of hospital follow-up, satisfaction survey, appointment reminder, and chronic disease management. It not only improves the efficiency of follow-up but also reduces work for doctors and improves patients' compliance with out-of-hospital treatment.

Founded in 1983, SVB works with technology, life science, cleantech, venture capital, private equity, and premium wine businesses. SVB provides industry knowledge and connections, financing, treasury management, corporate investment and international banking services to its clients worldwide through 27 U.S. offices and seven international operations.

Founded in 2018 and is headquartered in Beijing, China, Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors.